Cargando…

High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2

Since the beginning of the pandemic of COVID-19, there has been a widespread assumption that most infected persons are asymptomatic. Using data from the recent wave of the EPICOVID19 study, a nationwide household-based survey including 133 cities from all states of Brazil, we estimated the proportio...

Descripción completa

Detalles Bibliográficos
Autores principales: Menezes, Ana M. B., Victora, Cesar G., Hartwig, Fernando P., Silveira, Mariângela F., Horta, Bernardo L., Barros, Aluísio J. D., Mesenburg, Marilia A., Wehrmeister, Fernando C., Pellanda, Lúcia C., Dellagostin, Odir A., Struchiner, Cláudio J., Burattini, Marcelo N., Barros, Fernando C., Hallal, Pedro C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225900/
https://www.ncbi.nlm.nih.gov/pubmed/34168250
http://dx.doi.org/10.1038/s41598-021-92775-y
_version_ 1783712168095514624
author Menezes, Ana M. B.
Victora, Cesar G.
Hartwig, Fernando P.
Silveira, Mariângela F.
Horta, Bernardo L.
Barros, Aluísio J. D.
Mesenburg, Marilia A.
Wehrmeister, Fernando C.
Pellanda, Lúcia C.
Dellagostin, Odir A.
Struchiner, Cláudio J.
Burattini, Marcelo N.
Barros, Fernando C.
Hallal, Pedro C.
author_facet Menezes, Ana M. B.
Victora, Cesar G.
Hartwig, Fernando P.
Silveira, Mariângela F.
Horta, Bernardo L.
Barros, Aluísio J. D.
Mesenburg, Marilia A.
Wehrmeister, Fernando C.
Pellanda, Lúcia C.
Dellagostin, Odir A.
Struchiner, Cláudio J.
Burattini, Marcelo N.
Barros, Fernando C.
Hallal, Pedro C.
author_sort Menezes, Ana M. B.
collection PubMed
description Since the beginning of the pandemic of COVID-19, there has been a widespread assumption that most infected persons are asymptomatic. Using data from the recent wave of the EPICOVID19 study, a nationwide household-based survey including 133 cities from all states of Brazil, we estimated the proportion of people with and without antibodies for SARS-CoV-2 who were asymptomatic, which symptoms were most frequently reported, number of symptoms and the association with socio-demographic characteristics. We tested 33,205 subjects using a rapid antibody test previously validated. Information was collected before participants received the test result. Out of 849 (2.7%) participants positive for SARS-CoV-2 antibodies, only 12.1% (95% CI 10.1–14.5) reported no symptoms, compared to 42.2% (95% CI 41.7–42.8) among those negative. The largest difference between the two groups was observed for changes in smell/taste (56.5% versus 9.1%, a 6.2-fold difference). Changes in smell/taste, fever and body aches were most likely to predict positive tests as suggested by recursive partitioning tree analysis. Among individuals without any of these three symptoms, only 0.8% tested positive, compared to 18.3% of those with both fever and changes in smell or taste. Most subjects with antibodies against SARS-CoV-2 are symptomatic, even though most present only mild symptoms.
format Online
Article
Text
id pubmed-8225900
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82259002021-07-02 High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2 Menezes, Ana M. B. Victora, Cesar G. Hartwig, Fernando P. Silveira, Mariângela F. Horta, Bernardo L. Barros, Aluísio J. D. Mesenburg, Marilia A. Wehrmeister, Fernando C. Pellanda, Lúcia C. Dellagostin, Odir A. Struchiner, Cláudio J. Burattini, Marcelo N. Barros, Fernando C. Hallal, Pedro C. Sci Rep Article Since the beginning of the pandemic of COVID-19, there has been a widespread assumption that most infected persons are asymptomatic. Using data from the recent wave of the EPICOVID19 study, a nationwide household-based survey including 133 cities from all states of Brazil, we estimated the proportion of people with and without antibodies for SARS-CoV-2 who were asymptomatic, which symptoms were most frequently reported, number of symptoms and the association with socio-demographic characteristics. We tested 33,205 subjects using a rapid antibody test previously validated. Information was collected before participants received the test result. Out of 849 (2.7%) participants positive for SARS-CoV-2 antibodies, only 12.1% (95% CI 10.1–14.5) reported no symptoms, compared to 42.2% (95% CI 41.7–42.8) among those negative. The largest difference between the two groups was observed for changes in smell/taste (56.5% versus 9.1%, a 6.2-fold difference). Changes in smell/taste, fever and body aches were most likely to predict positive tests as suggested by recursive partitioning tree analysis. Among individuals without any of these three symptoms, only 0.8% tested positive, compared to 18.3% of those with both fever and changes in smell or taste. Most subjects with antibodies against SARS-CoV-2 are symptomatic, even though most present only mild symptoms. Nature Publishing Group UK 2021-06-24 /pmc/articles/PMC8225900/ /pubmed/34168250 http://dx.doi.org/10.1038/s41598-021-92775-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Menezes, Ana M. B.
Victora, Cesar G.
Hartwig, Fernando P.
Silveira, Mariângela F.
Horta, Bernardo L.
Barros, Aluísio J. D.
Mesenburg, Marilia A.
Wehrmeister, Fernando C.
Pellanda, Lúcia C.
Dellagostin, Odir A.
Struchiner, Cláudio J.
Burattini, Marcelo N.
Barros, Fernando C.
Hallal, Pedro C.
High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2
title High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2
title_full High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2
title_fullStr High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2
title_full_unstemmed High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2
title_short High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2
title_sort high prevalence of symptoms among brazilian subjects with antibodies against sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225900/
https://www.ncbi.nlm.nih.gov/pubmed/34168250
http://dx.doi.org/10.1038/s41598-021-92775-y
work_keys_str_mv AT menezesanamb highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT victoracesarg highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT hartwigfernandop highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT silveiramariangelaf highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT hortabernardol highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT barrosaluisiojd highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT mesenburgmariliaa highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT wehrmeisterfernandoc highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT pellandaluciac highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT dellagostinodira highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT struchinerclaudioj highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT burattinimarcelon highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT barrosfernandoc highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2
AT hallalpedroc highprevalenceofsymptomsamongbraziliansubjectswithantibodiesagainstsarscov2